PRMT1 methylates RIP3 to inhibit RIP1-RIP3 complex formation, resulting in the impaired RIP3 phosphorylation and necroptosis activation that builds the beneficial immune microenvironment against colon cancer growth (Fig. 5J). The gene discussed is RIPK1; the disease is colonic neoplasm.